GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » U2Bio Co Ltd (XKRX:221800) » Definitions » Gross-Profit-to-Asset %

U2Bio Co (XKRX:221800) Gross-Profit-to-Asset % : 12.65% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is U2Bio Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. U2Bio Co's annualized Gross Profit for the quarter that ended in Dec. 2023 was ₩5,911 Mil. U2Bio Co's average Total Assets over the quarter that ended in Dec. 2023 was ₩46,713 Mil. Therefore, U2Bio Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 12.65%.


U2Bio Co Gross-Profit-to-Asset % Historical Data

The historical data trend for U2Bio Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

U2Bio Co Gross-Profit-to-Asset % Chart

U2Bio Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only 13.04 23.60 50.73 57.68 16.40

U2Bio Co Semi-Annual Data
Jun22 Dec22 Jun23 Dec23
Gross-Profit-to-Asset % - 20.92 22.10 12.65

Competitive Comparison of U2Bio Co's Gross-Profit-to-Asset %

For the Diagnostics & Research subindustry, U2Bio Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


U2Bio Co's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, U2Bio Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where U2Bio Co's Gross-Profit-to-Asset % falls into.



U2Bio Co Gross-Profit-to-Asset % Calculation

U2Bio Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=8218.566/( (51028.368+49199.391)/ 2 )
=8218.566/50113.8795
=16.40 %

U2Bio Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=5911.014/( (44226.119+49199.391)/ 2 )
=5911.014/46712.755
=12.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


U2Bio Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of U2Bio Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


U2Bio Co (XKRX:221800) Business Description

Traded in Other Exchanges
N/A
Address
Basement 1, 68 Gumaro Songpagu, Seoul, KOR
U2Bio Co Ltd provides vitro diagnostic test services. The company is engaged in offering general diagnostic tests, molecular diagnostic tests, and breastfeeding nutritional analysis services among others.

U2Bio Co (XKRX:221800) Headlines

No Headlines